Evidence map›Paper›PMID 39967313›Full record

ArticleJournal of neurochemistry2025

A Pharmacophore for Drugs Targeting the α4α4 Binding Site of the (α4)

Ali S Kusay, Yujia Luo, Megan L O'Mara, Thomas Balle

Abstract read
In one paragraph

Article in Journal of neurochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ali S KusaySydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
Yujia LuoSydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
Megan L O'MaraResearch School of Chemistry, The Australian National University, Canberra, Australian Capital Territory, Australia.
Thomas BalleSydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.ORCID 0000-0002-0233-8350

Funding

National Computational InfrastructureSydney Informatics Hub
6 · The paper itself

Abstract

Neuronal nicotinic acetylcholine receptors (nAChRs) have an established role in pain pathways and devastating neurodegenerative diseases; however, few drugs have been successfully developed to target them. The most abundant nAChR in the brain, the α4β2 nAChR, is assembled from five subunits in a 3α:2β stoichiometry-(α4)

Indexed as

Nicotinic AgonistsReceptors, NicotinicAnimalsBinding SitesHumansOxadiazolesPharmacophorePyridines3-(3-(pyridine-3-yl)-1,2,4-oxadiazol-5-yl)benzonitrileNicotinic Agonistsnicotinic receptor alpha4beta2OxadiazolesPyridinesReceptors, NicotinicCMPImolecular dynamicsnicotinic acetylcholine receptorNS9283pharmacophoreα4α4 binding siteα4β2 nAChR

Identifiers

PMID39967313
PMCPMC11836552

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.